Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Johnston
S Claiborne
SC
Stroke Service, University of California, San Francisco, CA, USA. clay.johnston@ucsfmedctr.org
D000179:Acrylates / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control*; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009568:Nitrendipine / Q000627:therapeutic use*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000150:complications* / Q000401:mortality; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D000179:Acrylates; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan; D009568:Nitrendipine